Phase 3 study of PD-0332991 (Oral CDK4/6 inhibitor) plus Letrozole versus placebo plus Letrozole for postmenopausal women with ER (+), HER2 (-) breast cancer who have not received prior systemic anti cancer therapies

-
Investigator: Hope Rugo, MD
Sponsor: Pfizer

Location(s): United States

Description

The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.